Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Andrade-Gordon

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
The Journal of Pharmacology and Experimental Therapeutics|January 26, 1999
Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1B P Damiano, W M Cheung, R J Santulli, et al.
Nature Medicine|July 4, 2001
Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathwayN Vergnolle, N W Bunnett, K A Sharkey, et al.
British Journal of Pharmacology|August 7, 2001
Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanismL de Garavilla, N Vergnolle, S H Young, et al.
Thrombosis and Haemostasis|December 1, 1996
Biological consequences of thrombin receptor deficiency in miceA L Darrow, W P Fung-Leung, R D Ye, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 16, 2001
Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in ratsP Andrade-Gordon, C K Derian, B E Maryanoff, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 1999
Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptorP Andrade-Gordon, B E Maryanoff, C K Derian, et al.
Journal of Medicinal Chemistry|December 22, 1999
Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308W J Hoekstra, B E Maryanoff, B P Damiano, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
The Journal of Pharmacology and Experimental Therapeutics|January 26, 1999
Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1B P Damiano, W M Cheung, R J Santulli, et al.
Nature Medicine|July 4, 2001
Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathwayN Vergnolle, N W Bunnett, K A Sharkey, et al.
British Journal of Pharmacology|August 7, 2001
Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanismL de Garavilla, N Vergnolle, S H Young, et al.
Thrombosis and Haemostasis|December 1, 1996
Biological consequences of thrombin receptor deficiency in miceA L Darrow, W P Fung-Leung, R D Ye, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 16, 2001
Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in ratsP Andrade-Gordon, C K Derian, B E Maryanoff, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 1999
Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptorP Andrade-Gordon, B E Maryanoff, C K Derian, et al.
Journal of Medicinal Chemistry|December 22, 1999
Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308W J Hoekstra, B E Maryanoff, B P Damiano, et al.
Pageof 6